Corporate LiveWire acknowledges the importance of a patient-accepted CRC detection method to effectively diagnose colorectal cancer.
Berlin (Germany) and San Diego, CA (U.S.A.), May 9, 2019 – Epigenomics AG is honored to have Epi proColon® recognized as the 2019 Excellence in Molecular Diagnostics award by Corporate LiveWire as part of the Innovation and Excellence Awards. Corporate LiveWire annually recognizes the best developers, projects, and services from around the world. The awards span all industries from science and technology, to engineering, design and even finance, highlighting the best-of-the-best within each.
The selection panel acknowledge the importance of a patient-accepted colorectal cancer (CRC) detection method and wanted to commend Epigenomics for developing Epi proColon – a simple, viable and accessible solution to effectively screen for the disease. Knowing that CRC is the second highest killer in cancer related deaths and that the cause of so many of those deaths are due to lack of screening, a blood test is a fantastic solution that will help to save lives by increasing the accessibility of CRC screening.
“Epi proColon is the first FDA-approved cell free DNA (cfDNA) molecular assay for cancer,” said Greg Hamilton, Chief Executive Offer of Epigenomics AG. “In clinical application, a patient-accepted method will screen millions of Americans, thus impacting the stagnant U.S. screening rate and saving thousands of lives annually.”
About colorectal cancer (CRC)
Colorectal cancer remains a leading cause of cancer death in the United States. Although screening and early detection of colorectal cancer can save lives, about 35% of eligible U.S. patients are not being screened regularly. The unscreened population disproportionately results in 43% of new colorectal cancer cases and about 76% of colorectal cancer deaths and costs. Approximately $18 billion is spent annually on this preventable disease. Over $13 billion is spent on cases from unscreened individuals.
By increasing screening and detecting more cancers early, the costs and deaths from this disease both can be addressed.
About Epi proColon®
Epi proColon® is indicated for colorectal cancer screening in average-risk patients who are unwilling or unable to perform colorectal cancer screening by colonoscopy and stool-based methods.
For patients, the test only requires a simple blood sample draw as part of routine healthcare provider visits. There are no dietary restrictions or alterations in medication required for the test. The sample will be analyzed at a national or regional diagnostic laboratory.
For more information on Epi proColon, visit www.epiprocolon.com.
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung® and HCCBloodTest, blood-based tests for lung and liver cancer detection, has received CE mark in Europe.
For more information, visit www.epigenomics.com.
Contact in the U.S.
Director of Marketing
Contact Epigenomics AG
Phone +49 221 9140 970
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.